HC Wainwright & Co. Downgrades Freeline Therapeutics to Neutral, Lowers Price Target to $6.5
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Patrick Trucchio has downgraded Freeline Therapeutics (NASDAQ:FRLN) from Buy to Neutral and reduced the price target from $15 to $6.5.
November 28, 2023 | 12:10 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Freeline Therapeutics' stock rating was downgraded from Buy to Neutral by HC Wainwright & Co., and the price target was lowered from $15 to $6.5.
The downgrade from Buy to Neutral by a prominent analyst suggests a less optimistic outlook on FRLN's stock performance. The significant reduction in the price target could lead to a negative investor sentiment and a potential decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100